lobbying_activities: 2307672

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2307672	5e61b84a-8855-4636-907c-75eaec60e71d	Q2	KOUNTOUPES DENHAM CARR & REID, LLC	320918	GLENMARK PHARMACEUTICALS, INC., USA	2019	second_quarter	CPT	Issues related to the abuses of the patent system, extensions of drug exclusivity, pay-for-delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Ace of 2019, and H. R. 938, the BLOCKING Act of 2019.	HOUSE OF REPRESENTATIVES,SENATE	50000		0	0	2019-07-17T14:41:09.140000-04:00